Business
Syndax Pharmaceuticals to Host Conference Call and Webcast to Provide Updated Data from Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 in Patients with Acute Leukemias
- Event to be webcast live on Tuesday, April 20, 2021 at 8:00 a.m. ET - WALTHAM, Mass., April 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax,"
About this update from Syndax Pharmaceuticals, Inc.
[{"type":"text","content":"- Event to be webcast live on Tuesday, April 20, 2021 at 8:00 a.m. ET -\n\n\nWALTHAM, Mass., April 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (\"Syndax,\" the \"Company\" or \"we\") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will host a conference call and live webcast to provide updated data from the Phase 1 dose escalation portion of the ongoing Phase 1/2 AUGMENT-101 trial of SNDX-5613 in patients with relapsed or refractory acute leukemias on Tuesday, April 20, 2021 at 8:00 a.m. ET. SNDX-5613 is the Company's highly selective, oral menin inhibitor.\nThe event will feature the trial's principal investigator, Eytan M. Stein, M.D., Assistant Attending Physician and Director, Program for Drug Development in Leukemia, Department of Medicine at Memorial Sloan Kettering Cancer Center.\nConference Call and Webcast Details\nThe live video webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website at www.syndax.com. Alternatively, the conference call may be accessed through the following:\nConference ID: 3129568Domestic Dial-in Number: (877) 474-0326International Dial-in Number: (918) 922-6881Live webcast: https://onlinexperiences.com/Launch/QReg/ShowUUID=E0296F2E-256E-494B-A4F6-FD7220BACE26\nFor those unable to participate in the live event, a replay will be available on the Investors section of the Company's website, www.syndax.com.\nAbout Syndax Pharmaceuticals, Inc. \nSyndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor.\nSyndax's Cautionary Note on Forward-Looking Statements\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as \"may,\" \"will,\" \"expect,\" \"plan,\" \"anticipate,\" \"estimate,\" \"intend,\" \"believe\" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intend...